High Tech Pharm
하이텍팜 · 106190
Health Care Pharmaceuticals · KOSDAQ
Market cap US$116.8M (₩161.2B)
Overview
High Tech Pharm makes active pharmaceutical ingredients, the purified chemical compounds that drug manufacturers use to produce finished injectable antibiotics.
It specialises in carbapenem-class antibiotics, a group of broad-spectrum antibiotics used in hospitals to treat serious bacterial infections, with its main products being imipenem and ertapenem. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company supplies almost entirely to overseas pharmaceutical manufacturers, with Europe accounting for the large majority of its revenue.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$55.6M
- FY2024US$56.2M
- FY2025US$50.9M
Operating profit
- FY2023US$7.3M
- FY2024US$11.3M
- FY2025US$9.3M
Net income
- FY2023US$5.9M
- FY2024US$9.9M
- FY2025US$8.3M
Key ratios (FY2025)
Why it matters
The company applies a proprietary crystallisation process it says achieves higher yields and lower impurity levels than competing methods, which it treats as a core production differentiator.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?